United States - English - NLM (National Library of Medicine)

unit dose services - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)]. ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatien

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine t

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been ade

Malta - English - Medicines Authority

fresenius kabi limited - chromic chloride; copper chloride; ferric chloride; manganese chloride; potassium iodide; sodium fluoride; sodium molybdate dihydrate; sodium selenite; zinc chloride - concentrate for solution for infusion - chromic chloride 5.33 µg/ml; copper chloride 0.10 mg; ferric chloride 0.54 mg; manganese chloride 19.8 µg; potassium iodide 16.6 µg; sodium fluoride 0.21 mg; sodium molybdate dihydrate 4.85 µg; sodium selenite 17.3 µg; zinc chloride 1.05 mg - blood substitutes and perfusion solutions

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone hydrochloride capsule is an atypical antipsychotic. in choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the qt interval and may consider the use of other drugs first (5.2) ziprasidone hydrochloride capsule is indicated as an oral formulation for the treatment of schizophrenia. (1.1) adults: efficacy was established in 4 to 6 week trials and one maintenance trial in adult patients with schizophrenia  (14.1) because of ziprasidone's dose-related prolongation of the qt interval and the known association of fatal arrhythmias with qt prolongation by some other drugs, ziprasidone is contraindicated: - in patients with a known history of qt prolongation (including congenital long qt syndrome) - in patients with recent acute myocardial infarction - in patients with uncompensated heart failure pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the qt interval have not been performed. an additive eff

United States - English - NLM (National Library of Medicine)

hospira, inc. - chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - chromium 4 mcg/ml (chromic chloride injection, usp) is indicated for use as a supplement to intravenous solutions given for tpn. administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. none known. none known.

United States - English - NLM (National Library of Medicine)

hospira, inc. - chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - chromium 4 mcg/ml (chromic chloride injection, usp) is indicated for use as a supplement to intravenous solutions given for tpn. administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. none known. none known.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia,as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see war

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 45025 - catgut suture, chromic - chromic gut sutures are absorbable, sterile surgical sutures composed of purified connective tissue (mostly collagen) derived from the serosal layer of bovine intestines. they are packaged in a solution of 87% isopropanol, 12% water, and 1% triethanolamine. chromic and mild surgical gut sutures are treated with chromic salt solution. chromic gut sutures are intended for use in general soft tissue approximation and/or ligation, including use in ophthalmic surgery but not for use in cardiovascular or neurological surgery and microsurgery.

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - chromic chloride, copper chloride, ferric chloride, manganese chloride, potassium iodide, sodium fluoride, sodium molybdate, dihydrate, sodium selenite, zinc chloride - concentrate for solution for infusion - chromic chloride 5.33 µg/ml copper chloride 0.102 mg/ml ferric chloride 0.54 mg/ml manganese chloride 19.8 µg/ml potassium iodide 16.6 µg/ml sodium fluoride 0.21 mg/ml sodium molybdate dihydrate 4.85 µg/ml sodium selenite 17.3 µg/ml zinc chloride 1.05 mg/ml - blood substitutes and perfusion solutions